Phase 3 trial of Rybrevant plus chemotherapy in lung cancer meets primary endpoint: Janssen Ruchika Sharma18 July 2023 1:30 PM ISTNew Jersey: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the Phase 3 PAPILLON study ...
Janssen seeks USFDA nod for Carvykti for relapsed or refractory multiple myeloma Ruchika Sharma8 Jun 2023 12:30 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental Biologics License...
Janssen Milvexian gets USFDA fast track designation for Ischemic Stroke, Acute Coronary Syndrome, Atrial Fibrillation Ruchika Sharma26 May 2023 3:15 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that all three prospective indications for milvexian, an ...
Janssen gets European Commission nod for AKEEGA to treat metastatic castration resistant prostate cancer with BRCA1/2 mutations Ruchika Sharma22 April 2023 11:32 AM ISTThe EC authorisation, which also marks the first worldwide approval for AKEEGA, is based on results of the randomised, double-blind, placebo...
Bristol Myers Squibb, Janssen launch Phase 3 Librexia clinical trial program evaluating Milvexian Ruchika Sharma5 March 2023 2:30 PM ISTPrinceton: Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson...
Janssen seeks USFDA nod for Niraparib and Abiraterone Acetate Dual-Action Tablet, plus Prednisone to treat patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Gene Mutations Ruchika Sharma2 March 2023 3:15 PM ISTMetastatic castration-resistant prostate cancer characterizes cancer that no longer responds to androgen deprivation therapy and has spread to other...
Janssen, Global Partners to discontinue Phase 3 Mosaico HIV vaccine trial Ruchika Sharma19 Jan 2023 4:15 PM ISTLeiden: The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, has announced the results of an...
Janssen seeks USFDA nod for Multiple myeloma treatment Talquetamab Ruchika Sharma11 Dec 2022 1:00 PM ISTRaritan, N.J.: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a Biologics License Application...
Janssen bags USFDA nod for IMBRUVICA for chronic graft-versus-host disease treatment Ruchika Sharma28 Aug 2022 12:45 PM ISTChronic graft-versus-host disease is a life-threatening complication that can occur after a stem cell or bone marrow transplant when newly...
Janssen bags USFDA nod for psoriatic arthritis treatment STELARA for pediatric patients Rahul Verma6 Aug 2022 8:16 PM ISTThe Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the U.S. Food and Drug Administration (USFDA) has approved STELARA...
Janssen gets USFDA nod for psoriatic arthritis treatment STELARA for pediatric patients Ruchika Sharma4 Aug 2022 11:46 AM ISTSTELARA is administered as a subcutaneous injection dosed four times per year after two starter doses for the treatment of pediatric patients six...
Janssen Pharma gets USFDA Breakthrough Therapy Designation for Multiple Myeloma treatment Talquetamab Ruchika Sharma30 Jun 2022 3:02 PM ISTTalquetamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting both GPRC5D, a novel drug target, on multiple...
